. Astra-zeneca and P. Merck, J-PG has been a consultant to Astellas, Gilead, Merck and Pfizer. DG has benefited from grants of the Principalty of Monaco to his research unit

. Astellas, M. Gilead, and L. , PM has been a consultant to Astra-Zeneca, Tetraphase and TMC. P-FP has been a consultant to MSD and Pfizer

M. Gilead and 3. Bayer, has benefited from unrestricted research grants to his research unit from 3M, MSD, and Astellas; and has been a consultant involved in scientific boards for

S. Lagny and . Marne, Delpierre, Demory

. Ichai, Levy (Vandoeuvre-lès-Nancy), Luyt (Paris), Mahe (Nantes), Mahul, Kaidomar (Fréjus) Leroy (Tourcoing), Lesieur (La Rochelle) Mateu (Charleville-Mézières) Montcriol (Toulon), Mootien (Mulhouse), Navellou (Besançon), Ouattara (Pessac), Page (Boulogne), Perrigault (Montpellier), Petitpas (Poitiers), Plantefeve (Argenteuil), Quinart (Bordeaux), Quintard (Nice), Ragonnet (Marseille), Roquilly (Nantes), Ruiz (Toulouse), Saliba (Villejuif) Schmitt (Lyon) Sejourne (Dechy), Tellier (Chambray-les-Tours), Thevenot (Perpignan), Tonnelier (Brest), Van Grunderbeek (Lens) Wiramus (Marseille), and Zogheib

P. Pappas, C. Kauffman, and D. Andes, Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of america, Clin Infect Dis, issue.2, 2015.

O. Cornely, M. Bassetti, and T. Calandra, ESCMID* *This guideline was presented in part at ECCMID 2011. European Society for Clinical Microbiology and Infectious Diseases. guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients, Clinical Microbiology and Infection, vol.18, issue.7, pp.19-37, 2012.
DOI : 10.1111/1469-0691.12039

O. Leroy, J. Gangneux, and P. Montravers, Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: A multicenter, prospective, observational study in France (2005???2006), Critical Care Medicine, vol.37, issue.5, pp.1612-1618, 2005.
DOI : 10.1097/CCM.0b013e31819efac0
URL : https://hal.archives-ouvertes.fr/hal-00676899

O. Lortholary, C. Renaudat, and K. Sitbon, Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002???2010), Intensive Care Medicine, vol.51, issue.Suppl 7, pp.1303-1312, 2002.
DOI : 10.1128/AAC.00474-06
URL : https://hal.archives-ouvertes.fr/pasteur-01405246

S. Bailly, D. Maubon, and P. Fournier, Impact of antifungal prescription on relative distribution and susceptibility of Candida spp. ??? Trends over 10 years, Journal of Infection, vol.72, issue.1, pp.103-111, 2016.
DOI : 10.1016/j.jinf.2015.09.041
URL : https://hal.archives-ouvertes.fr/hal-01470816

P. Fournier, C. Schwebel, and D. Maubon, Antifungal use influences Candida species distribution and susceptibility in the intensive care unit, Journal of Antimicrobial Chemotherapy, vol.66, issue.12, pp.2880-2886, 2011.
DOI : 10.1093/jac/dkr394
URL : https://hal.archives-ouvertes.fr/hal-00818509

B. Alexander, M. Johnson, and C. Pfeiffer, Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations, Clinical Infectious Diseases, vol.56, issue.12, pp.1724-1732, 2013.
DOI : 10.1093/cid/cit136

P. Munoz, M. Valerio, A. Vena, and E. Bouza, Antifungal stewardship in daily practice and health economic implications, Mycoses, vol.52, issue.Suppl. 3, pp.14-25, 2015.
DOI : 10.1093/mmy/myt025

J. Mora-duarte, R. Betts, and C. Rotstein, Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis, New England Journal of Medicine, vol.347, issue.25, pp.2020-2029, 2002.
DOI : 10.1056/NEJMoa021585

E. Kuse, P. Chetchotisakd, and C. Da-cunha, Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial, The Lancet, vol.369, issue.9572, pp.1519-1527, 2007.
DOI : 10.1016/S0140-6736(07)60605-9

A. Reboli, C. Rotstein, and P. Pappas, Anidulafungin versus Fluconazole for Invasive Candidiasis, New England Journal of Medicine, vol.356, issue.24, pp.2472-2482, 2007.
DOI : 10.1056/NEJMoa066906

D. Kett, A. Shorr, A. Reboli, A. Reisman, P. Biswas et al., Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: Support for the 2009 IDSA treatment guidelines for candidiasis, Critical Care, vol.15, issue.5, pp.253-266, 2011.
DOI : 10.1186/cc8117

S. Bailly, O. Leroy, and P. Montravers, Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data, Intensive Care Medicine, vol.18, issue.11, pp.1931-1940, 2015.
DOI : 10.1186/cc13953
URL : https://hal.archives-ouvertes.fr/hal-01205360

O. Leroy, S. Bailly, and J. Gangneux, Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study, Annals of Intensive Care, vol.29, issue.12, pp.2-15, 2016.
DOI : 10.1007/s00134-003-2002-x
URL : https://hal.archives-ouvertes.fr/hal-01259216

S. Bailly, R. Pirracchio, and J. Timsit, What???s new in the quantification of causal effects from longitudinal cohort studies: a brief introduction to marginal structural models for intensivists, Intensive Care Medicine, vol.68, issue.4, 2015.
DOI : 10.1111/j.1541-0420.2011.01685.x

P. Pappas, C. Kauffman, and D. Andes, Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America, Clinical Infectious Diseases, vol.48, issue.5, pp.503-535, 2009.
DOI : 10.1086/596757

J. Wang, Y. Xue, X. Zhu, and H. Fan, Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs, European Journal of Clinical Microbiology & Infectious Diseases, vol.356, issue.4, pp.651-659, 2015.
DOI : 10.1056/NEJMoa061098

P. Kale-pradhan, G. Morgan, S. Wilhelm, and L. Johnson, Infections: A Meta-analysis, Pharmacotherapy, vol.15, issue.12, pp.1207-1213, 2010.
DOI : 10.1086/376906

L. Lagunes, B. Borgatta, and M. Martin-gomez, Predictors of choice of initial antifungal treatment in intraabdominal candidiasis, Clinical Microbiology and Infection, vol.22, issue.8, p.20, 2016.
DOI : 10.1016/j.cmi.2016.06.005

J. Timsit, E. Azoulay, and C. Schwebel, Colonization, and Multiple Organ Failure, JAMA, vol.316, issue.15, 1921.
DOI : 10.1001/jama.2016.14655
URL : https://hal.archives-ouvertes.fr/hal-01405822

M. Bassetti, E. Righi, and F. Ansaldi, A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality, Intensive Care Medicine, vol.51, issue.8, pp.839-845, 2014.
DOI : 10.1086/653935

K. Garey, M. Rege, and M. Pai, Time to Initiation of Fluconazole Therapy Impacts Mortality in Patients with Candidemia: A Multi???Institutional Study, Clinical Infectious Diseases, vol.43, issue.1, pp.25-31, 2006.
DOI : 10.1086/504810

M. Sinnollareddy, S. Peake, M. Roberts, . J. Lipman, and J. Roberts, Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review, International Journal of Antimicrobial Agents, vol.39, issue.1, pp.1-10, 2012.
DOI : 10.1016/j.ijantimicag.2011.07.013